Researchers at the Cedars-Sinai Medical Center have identified a 10-gene biomarker panel that may identify the aggressiveness of a patient's ovarian cancer, help predict survival outcomes, and result in novel therapeutic strategies.
FDA is scheduled to review Exact Science's Cologuard stool-based colorectal screening test in March. The company's pre-submission clinical trial was one of the largest colorectal screenings conducted in the United States.
Proponents of personal genome testing envision a future enlightened by the tools of personalized medicine. But after issuing a warning letter to personal genomics leader 23andMe, FDA may not be seeing that future in quite the same light.
In its annual fee schedules for 2014, the Centers for Medicare and Medicaid Services deferred—but didn’t kill—implementation of its proposal to limit some independent lab payment rates to outpatient prospective payment system levels.
Thermo Fisher Scientific has announced it will shed its cell culture (sera and media), gene modulation, and magnetic beads businesses in order to expedite its $13.6 billion purchase of Life Technologies.
A new study shows that physicians order the greatest number of diagnostic procedures when electronic medical systems prepopulate lab test selections for them. The results suggest that cost savings may lie in eliminating the power of suggestion.
Researchers at the University of Massachusetts Medical School have discovered how to use DNA fragments' 3-dimensional structure and interaction frequency to situate 65 previously unaccounted for pieces within the human genome.
Researchers using the IsoFlux System have retrieved rare tumor cells from peripheral blood in early non-small cell lung cancer patients for molecular analysis. The study found that gross tumor volume positively correlated with CTC count.
It's rare when a milestone in medical technology attracts much attention among the nation's top healthcare brass. But last week, several paused to acknowledge FDA's clearance of the first high-throughput gene sequencer for clinical lab use.
Bio-Rad Laboratories and Invetech have announced a decade-long extension to their professional relationship, bringing their total collaboration to 25 years. The companies will continue producing the BioPlex 2200.
My name is Steve Halasey, and I'm pleased to be the incoming editor for a team that is committed to improving healthcare--starting with clinical diagnostics. Your input will help CLP to continue its tradition of serving the laboratory community.
Contact us about this feature or to become an expert.
CLP is the only magazine that focuses exclusively on products and technology for the clinical lab industry. Every month, CLP's editorial provides 45,000 pathologists, lab managers, administrators and technologists with comprehensive coverage of new products and technology.